Rapid health technology assessment of ulinastatin in the treatment of acute pancreatitis
- VernacularTitle:乌司他丁治疗急性胰腺炎的快速卫生技术评估
- Author:
Zihui ZHENG
1
;
Zinan ZHAO
1
;
Feng GAO
2
;
Wenying LI
1
;
Han YUAN
1
;
Baige ZHANG
1
;
Liping YANG
1
;
Pengfei JIN
1
Author Information
1. Dept. of Pharmacy，Beijing Hospital/National Geriatric Center/Institute of Geriatrics，Chinese Academy of Medical Sciences/Beijing Key Laboratory of Clinical Risk and Individualized Application Evaluation of Drugs （Beijing Hospital），Beijing 100730，China
2. Health Care Department，Security Bureau of Joint Staff Department of the Central Military Commission，Beijing 100173，China
- Publication Type:Journal Article
- Keywords:
ulinastatin;
acute pancreatitis;
efficacy;
safety;
cost-effectiveness;
rapid health technology assessment;
evidence-
- From:
China Pharmacy
2024;35(21):2676-2683
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE To conduct rapid health technology assessment （HTA） of ulinastatin （UTI）， and to evaluate the efficacy， safety and cost-effectiveness of UTI in the treatment of acute pancreatitis （AP）. METHODS Retrieved from PubMed， Embase， the Cochrane Library， CNKI， Wanfang database， CBM and official websites of HTA institutions， the systematic review （SR）/meta-analysis， economic evaluation and HTA reports of UTI in the treatment of AP were collected from the inception to Apr. 2024. Two researchers independently conducted screening， quality evaluation and data extraction according to the admission and exclusion criteria， and descriptive analysis was adopted to analyze and summarize the data. RESULTS A total of 19 studies were included， involving 15 SR/meta-analysis and 4 economic studies， and no HTA report was retrieved. In the treatment of AP， UTI showed clear advantages over conventional treatment alone in terms of improving the overall effective rate， shortening the recovery time of amylase， reducing the time required to relieve abdominal pain and distension， lowering the mortality rate， and decreasing the average hospital stay. Compared to other positive drugs （carbendate mesylate， octreotide， somatostatin， etc.）， its efficacy is similar， with a favorable safety profile. As far as the current research was concerned， UTI had obvious economic advantages over other positive drugs. CONCLUSIONS UTI is safe and effective in the treatment of AP， and has economic advantages.
